NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AA-24-013 from the NIH Guide for Grants and Contracts
Notice NOT-AG-24-077 from the NIH Guide for Grants and Contracts
Notice NOT-DC-25-003 from the NIH Guide for Grants and Contracts
Notice NOT-PM-25-001 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-24-011 from the NIH Guide for Grants and Contracts. The Molecular Transducers of Physical Activity Consortium (MoTrPAC) has made data available through the MoTrPAC Data Hub (http://MoTrPAC-data.org). The purpose of this NOFO is to announce the availability of funding to support novel approaches for analyzing MoTrPAC data, to generate hypotheses and catalyze discoveries; for comparing the publicly released MoTrPAC data to other datasets; and for developing analytic pipelines.
Funding Opportunity RFA-MH-26-140 from the NIH Guide for Grants and Contracts. This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack of quantitative approaches and models to understand the complexity of human and animal behavior in naturalistic settings. This NOFO focuses on the development of next generation sensors to acquire data and synchronize it with simultaneous brain recordings to build computational models.
Notice NOT-NS-25-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-24-009 from the NIH Guide for Grants and Contracts. The Common Fund Human Virome Program aims to extensively characterize the human virome and create tools, models, and methods that will enable an in-depth study of its variation in relation to host factors and its influence on health and disease. The purpose of this NOFO is to address the technological challenges that are currently hindering robust interrogation of the constituents and functionality of the human virome. Despite major advances in sequencing technology and computational analysis of large sequence data sets, challenges remain in examining viruses. This NOFO solicits applications to develop innovative and novel tools, models, and methods to overcome the major challenges in identifying and characterizing viruses, as well as the development of computational and bioinformatics tools to enhance the analysis of the human virome. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.
Funding Opportunity RFA-AI-24-069 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). These Centers will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R and D) and advancing phage clinical research.
Funding Opportunity PAR-25-057 from the NIH Guide for Grants and Contracts. To support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR)
Funding Opportunity PA-25-212 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Notice of Funding Opportunity (NOFO), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.
Funding Opportunity PAR-25-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Funding Opportunity PAR-25-058 from the NIH Guide for Grants and Contracts. Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Funding Opportunity PAR-25-060 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Notice NOT-OD-25-013 from the NIH Guide for Grants and Contracts
Notice NOT-AG-24-068 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-115 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-114 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-113 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-112 from the NIH Guide for Grants and Contracts